Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial.

MLA

Cohen, J. L., et al. “Improved Left Ventricular Endocardial Border Delineation and Opacification with OPTISON (FS069), a New Echocardiographic Contrast Agent. Results of a Phase III Multicenter Trial.” Journal of the American College of Cardiology, vol. 32, no. 3, Sept. 1998, pp. 746–52. EBSCOhost, https://doi.org/10.1016/s0735-1097(98)00311-8.

APA

Cohen, J. L., Cheirif, J., Segar, D. S., Gillam, L. D., Gottdiener, J. S., Hausnerova, E., & Bruns, D. E. (1998). Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial. Journal of the American College of Cardiology, 32(3), 746–752. https://doi.org/10.1016/s0735-1097(98)00311-8

Chicago

Cohen, J L, J Cheirif, D S Segar, L D Gillam, J S Gottdiener, E Hausnerova, and D E Bruns. 1998. “Improved Left Ventricular Endocardial Border Delineation and Opacification with OPTISON (FS069), a New Echocardiographic Contrast Agent. Results of a Phase III Multicenter Trial.” Journal of the American College of Cardiology 32 (3): 746–52. doi:10.1016/s0735-1097(98)00311-8.